CureVac N.V.

Greetings and welcome to the CureVac fourth quarter and full year 2022 financial results conference call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Sarah Fauci, Vice President, Corporate Communications and Investor Relations. Thank you. You may begin.

Thank you. Good morning, good afternoon, and welcome to our conference call. My name is Sarah Farkey, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers. On the call with me from CureVac are Alexander Zehnder, Chief Executive Officer of CureVac, Miriam Mendila, our Chief Development Officer, and Pierre Quimoulin, Chief Financial Officer of CureVac. Please note that this call is being webcast live and will be archived on the events and presentation section under investor relations on our website. Before we begin, a few forward looking statements. The discussion and responses to your questions on this call reflect management's view as of today, Tuesday, April 25th, 2023. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations, or predictions of the future. These constitute forward-looking statements for the purpose of the safe harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. CureVac disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Alexander.

Thank you, Sarah. Ladies and gentlemen, good morning, good afternoon to everybody on the webcast. On April 1st this year, I took over the leadership of CureVac, the pioneer in mRNA technology and the company that is at an inflection point, transforming from a research-oriented biotech to a fully integrated commercial biopharma company. Positive preliminary clinical data in our prophylactic vaccines area reported earlier this year have demonstrated the great potential of our proprietary mRNA platform. This critical milestone opens the door for CureVac to explore new opportunities in the development of effective vaccines and therapeutics, and we are now entering a new chapter of our corporate evolution. So I'm really thrilled to bring my strategic vision and strong operational and commercial experience to CureVac at this pivotal moment for the company. Please let me take the opportunity to briefly introduce myself. I'm a medical doctor by training, and I've worked in the pharmaceutical industry for more than 20 years across different companies, culture, disease areas, in roles of increasing complexity and responsibility. I had the great fortune to learn and grow in positions held at industry stalwarts such as Roche, Genentech, and Sanofi, in product strategy and commercially focused positions across multiple business units and functional areas. Most recently, before joining CureVac, I led the global oncology franchise at Sanofi. I was responsible for shaping one of the company's key future growth drivers, rebuilding the product pipeline, launching new medicines, strengthening the organization, and representing the company. And I am convinced that my experience in bringing practice-changing medicines to the market, building pipelines, and shaping organizations will be of great benefit as we take CureVac to the next level as a relevant commercial player. And I'm really honored to pursue this mission in collaboration with all our RNA people, as well as my colleagues from the CureVac management team, which was strengthened in February this year by the addition of Miriam Mandela as our chief development officer. So before I go into the quarterly review, I would also like to give Miriam the opportunity to briefly introduce herself.